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ABSTRACT
Infection with Helicobacter pylori is strongly associated with a number of gastroduodenal pathologies. Anti-
microbial resistance to commonly-used drugs has generated a considerable interest in the search for novel 
therapeutic compounds from medicinal plants. As an ongoing effort of this search, the susceptibility of 32 
clinical strains of H. pylori and a reference strain—NCTC 11638—was evaluated against five solvent ex-
tracts of Combretum molle, a plant widely used for the treatment of gastric ulcers and other stomach-related 
morbidities in South Africa. The extracts were screened for activity by the agar-well diffusion method, and 
the most active one of them was tested against the same strains by micro-broth dilution and time kill as-
says. Metronidazole and amoxicillin were included in these experiments as positive control antibiotics. The 
solvent extracts all demonstrated anti-H. pylori activity with zone diameters of inhibition between 0 and 
38 mm. The most potent anti-H. pylori activity was demonstrated by the acetone extract, to which 87.5% 
of the clinical strains were susceptible. The minimum inhibitory concentration (MIC90) values for this 
extract ranged from 1.25 to 5.0 mg/mL while those for amoxicillin and metronidazole ranged from 0.001 
to 0.94 mg/mL and from 0.004 to 5.0 mg/mL respectively. The acetone extract was highly bactericidal at a 
concentration of 2.5 and 5.0 mg/mL, with complete elimination of the test organisms in 24 hours. Its in-
hibitory activity was better than that of metronidazole (p<0.05) as opposed to amoxicillin (p<0.05). The 
results demonstrate that C. molle may contain therapeutically-useful compounds against H. pylori, which 
are mostly concentrated in the acetone extract. 
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INTRODUCTION
Helicobacter pylori is a gram-negative microaerophi- 
lic spiral-shaped bacillus that affects the gastric 
mucosa and can be found attached to epithelial 
cells of the human stomach (1). Infection with this 
organism is strongly associated with chronic gastri-
tis, peptic ulcer, duodenal ulcer, gastric adenocar-
cinoma, and mucosa-associated lymphoid tissue 
(MALT) lymphoma (2). The stomach of half of the 
world’s population is colonized by this organism 
(3). Treatment of H. pylori infection is relatively suc-
cessful, with up to 90% of patients exhibiting eradi-
cation of the organism with current therapeutic 
regimens (4). These regimens typically involve the 
use of a proton pump inhibitor (PPI) or bismuth 
compounds in combination with two antibiotics—
most commonly amoxicillin and clarithromycin, 
or metronidazole (5). However, H. pylori infection 
continues to be difficult to eradicate with failure 
rates of up to 40% (6). A major factor to this failure 
is the development of antibiotic-resistant strains 
(5). It is, therefore, not uncommon to find other 
stronger antibiotics, particularly of the fluoroqui-
nolone group, being part of the treatment regimen 
(7) but H. pylori is also developing resistance to Anti-Helicobacter pylori activity of Combretum molle Njume C et al.
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these drugs (8). Considering that eradication thera-
pies can be ineffective and undesirable side-effects 
may occur (9), the search for alternative therapeu-
tic sources for the development of new anti-H. py-
lori compounds is imperative.
Other factors, including poor compliance by pa-
tients, cost of combination therapy, the location of 
the organism in the stomach, and the non-availa-
bility of drugs in some rural settings in Africa, are 
contraindications for some patients (3,10). Equally 
important is the increasing prevalence of virulent 
strains, particularly those expressing the cytotoxin-
associated gene A antigen (CagA) associated with 
severe pathological conditions (11) that may be 
difficult to manage and post-therapeutic antibiotic 
resistance which has been known to decrease the 
cure rate by more than 50% (12). These factors have 
generated a considerable interest in the search for 
alternative treatment regimens against this notori-
ous pathogen. Alternative therapeutic agents with 
highly-selective antibacterial activity against the 
organism, without the risk of resistance or other 
untoward effects, are necessary (5).  
Medicinal plants are among the attractive sources 
of new drugs and have been used for treating gas-
trointestinal diseases and other ailments, particu-
larly in the developing world where infectious dis-
eases are endemic and modern health facilities are 
not always adequate or accessible (13). Antimicro-
bial compounds from plants may inhibit bacterial 
growth by mechanisms different from presently-
used treatment regimens and could, therefore, be 
of clinical value in the treatment of resistant bac-
teria, including H. pylori. In fact, our previous stud-
ies have documented that some medicinal plant 
extracts have antibacterial activity against H. pylori 
(14).
The genus Combretum is mainly tropical and con-
sists of numerous species, including Combretum 
molle, C. woodii, C. erythophyllum, C. Apiculatum, 
and C. mossambicense (15,16). They consist of trees, 
climbers, and shrubs (16). Almost every part of 
these plants—roots, leaves, seeds, and stem barks—
is used in African traditional medicine for the treat-
ment of parasitic, bacterial and fungal infections 
(15,16). The stem bark of C. molle, a small graceful 
deciduous tree (3-13 m high) is popularly used in 
South Africa for the treatment of stomach pains, 
dysentery, gastric ulcers, abdominal disorders, and 
other illnesses (15). Studies on its antibacterial 
properties have produced promising results (15). It 
is found in the traditional medicine market where it 
is commercialized for medicinal purposes. Despite 
its traditional uses in the treatment of gastric ulcers 
and other stomach-related morbidities, the activity 
of this plant has not been investigated against H. 
pylori, a major cause of gastric ulcer. This is surpris-
ing particularly as the prevalence of this organism 
is reported to vary between 50% and 80%  in South 
Africa (17,18), and an alarming resistance of 95.5% 
has been reported in South Africa for metronida-
zole, one of the antibiotics used  in the treatment 
regimen of H. pylori infections (4). This study was, 
therefore, carried out to evaluate the antimicrobial 
activity of C. molle on drug-resistant isolates of H. 
pylori. The aim was to identify the potential sources 
of cheap starting materials for the synthesis of new 
drugs that could be cheap and readily available to 
help circumvent the problem of increasing antimi-
crobial resistance. 
MATERIALS AND METHODS
Bacterial strains
We  used  32  resistant  strains  of  H.  pylori  isolated 
from  gastric  biopsies  of  patients  with  recurrent 
peptic ulcer infection, despite treatment with met-
ronidazole and amoxicillin, undergoing endoscopy 
at the Livingstone Hospital, Port Elizabeth. A stand-
ard control strain—NCTC 11638—was also includ-
ed. Isolation and identification was done following 
our previously-reported scheme (4). Briefly, biopsies 
were homogenized under aseptic conditions in 0.2 
g/L of cysteine and 20% of glycerol in Brain heart 
infusion (BHI) broth (Oxoid, England). A loopful 
of the homogenate was plated on freshly-prepared 
Columbia agar base (Oxoid, England) supplement-
ed with 6% horse blood and Skirrow’s supplement 
(Oxoid, England) containing trimethoprim (2.5 
mg), vancomycin (5 mg), cefsulodin (2.5 mg), and 
amphotericin (2.5 mg). Inoculated plates were incu-
bated at 37 ºC for five days under microaerophilic 
conditions (5-6% O2, 10% CO2, and 80-85% N2)   
(Anaerocult Basingstoke, Hampshire, England). 
The isolates were identified based on colony mor-
phology, positive oxidase, urease, catalase tests, and 
amplification of the glmM gene. Confirmed isolates 
were suspended in eppendorf tubes containing 1 
mL of BHI broth and 20% glycerol and stored at 
-80 oC until future use. Gastric biopsies were only 
collected from patients who had given consent and 
had not been on antibiotics, PPI, or bismuth salts 
for at least a week. 
Preparation of plant material
The stem bark of C. molle R. Br. Ex G. Don (Combre-
taceae) was harvested in the vicinity of the Univer-
sity of Venda, Limpopo province, and transported 
in plastic bags to the School of Biological Sciences, 
University of Fort Hare, where they were identi-
fied and vouchers were deposited in the school’s 
herbarium (CNUFH05). The plant material was Njume C et al. Anti-Helicobacter pylori activity of Combretum molle
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washed, air-dried for two weeks, and ground to 
fine powder using a blender (ATO MSE mix, Eng-
land). 
Preparation of plant extracts
Exactly 300 g of dried plant material was macera- 
ted separately in 600 mL of concentrated ethyl ace- 
tate, acetone, ethanol, and methanol in large glass 
bottles (SIMAX, Czech Republic). Aqueous extracts 
were also prepared by soaking the same amount 
of plant material in tap water. The bottles were la-
belled and put in an orbital shaker for 48 hours. 
The plant extracts were centrifuged at 1,006.2 g 
for five minutes at 4 ºC and filtered using a fritted 
filter funnel of pore size 60 Å. The procedure was 
repeated twice, and the three extracts were com-
bined and evaporated to dryness under vacuum 
in a rotary evaporator (BUCHI rota vapour, Flavil/
Schweiz, Switzerland). The filtrate obtained from 
the aqueous extract was lyophilized (19). The dried 
crude extracts were collected in clean glass Petri-
dishes and left open in a biosafety class II cabinet 
(Durban, South Africa) for complete evaporation of 
residual solvents. A 2-g sample of each extract was 
used for the preliminary bioassay, and where pos-
sible, another 2 g or more was put in universal bot-
tles and kept in the extract bank. Stock solutions 
were prepared by dissolving the extracts in 10% 
dimethyl sulphoxide (DMSO) or 80% acetone (nei-
ther DMSO nor acetone was inhibitory to the H. 
pylori strains at the tested concentrations).
Screening of crude extracts for anti-H. pylori 
activity
This was done by the agar-well diffusion method 
as previously reported (20). Briefly, H. pylori inocula 
prepared at McFarland’s turbidity standard 2 were 
plated onto BHI agar supplemented with 5% horse 
blood and Skirrow’s supplement (Oxoid, England). 
The inocula were evenly spread on the plate. The 
plate  was  allowed  to  dry  for  about  15  minutes. 
Wells (6 mm in diameter) were punched into the 
agar using a sterile stainless steel borer. The wells 
were filled with 65 µL of the extract at 100 mg/mL. 
Sixty-five µL of 0.05 µg/mL of clarithromycin and 
10% DMSO were included in all the experiments 
as positive and negative controls respectively. The 
plates were incubated under microaerophilic con-
ditions  (Anaerocult,  Oxoid,  UK)  at  37  oC  for  72 
hours after which the diameters of zones of inhibi-
tion were measured in mm. The experiment was 
repeated once, and the mean zones were recorded. 
A zone diameter of ≥14 mm was used as breakpoint 
susceptibility for clarithromycin and the extracts; 
this was also used for calculating their percentage 
susceptibilities (1). A plate inoculated with a refer-
ence strain (NCTC 11638) of H. pylori was included 
in all the experimental runs.
Determination of minimum inhibitory 
concentration (MIC90)
The acetone extract which was the only extract to 
which more than 50% of the strains were suscepti-
ble was chosen for further determination of MIC by 
the micro-broth dilution method as earlier report-
ed (21). The test was performed in 96-well plates. 
The test extract was prepared at a concentration 
of 5.0 mg/mL and filtered through a 2.0-µm filter 
(Acrodisc Pall, MI, USA). Two-fold dilutions of the 
extract were made in the test wells in BHI broth 
supplemented with 5% horse serum and Skirrow’s 
supplement (Oxoid, England). The final extract 
concentration ranged from 0.001 to 5.0 mg/mL. 
Twenty µL of an 18-hour old broth culture of H. py-
lori (McFarland’s turbidity standard 2) suspension 
was added to 100 µL of extract-containing culture 
medium. Control wells were prepared with cul-
ture medium plus bacterial suspension and broth 
only respectively. Metronidazole and amoxicillin 
were run, alongside the extract at concentration 
ranges of 0.005-5.0 mg/mL and 0.001-1.25 mg/
mL respectively. An automatic ELISA micro-plate 
reader (Tokyo, Japan) adjusted to 620 nm was used 
for measuring the absorbance of the plates. The 
plates were incubated at 37 °C for 72 hours under 
microaerophilic conditions (Anaerocult Basing-
stoke, Hampshire, England), and the absorbance 
was read again at 620 nm. The initial and the post-
incubation absorbencies were compared to detect 
an increase or a decrease in bacterial growth. The 
lowest concentration of the test extract resulting in 
inhibition of 90% of bacterial growth was recorded 
as the MIC. The strains were considered susceptible 
to the control antibiotics if their MIC90 values were 
<0.002 mg/mL for amoxicillin and <0.008 mg/mL 
for metronidazole (1).  
Determination of rate of killing
The rate and extent of killing of H. pylori by the 
acetone extract of C. molle was determined as des- 
cribed by Akinpelu et al. (22) with slight modifica-
tions. The turbidity of an 18-hour old broth cul-
ture of H. pylori was standardized to 108 CFU/mL. 
One mL of this suspension was added to 9 mL of 
BHI broth supplemented with 5% horse serum and 
Skirrow’s reagents containing the extract at 0.625 
mg/mL (MIC/2), 1.25 mg/mL (MIC), 2.50 mg/mL 
(2 MIC), and 5.0 mg/mL (4 MIC) in McCartney bot-
tles (Oxoid, England). A negative control bottle was 
prepared with bacterial suspension and broth only. 
A 0.1-mL sample was plated from these bottles 
before incubation at 37 °C under microaerophilic   
conditions. Exactly 0.5 mL of each suspension was 
withdrawn at a six-hour interval for 72 hours and 
transferred to 4.5 mL of BHI broth recovery medium Anti-Helicobacter pylori activity of Combretum molle Njume C et al.
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containing 3% ‘Tween 80’ to neutralize the effects 
of the antimicrobial extract carry-overs from the 
test organisms. The suspension was 10-fold serially 
diluted in sterile saline (0.9% w/v sodium chloride) 
and plated in triplicates. The plates were incubated 
at 37 °C for 72 hours under microaerophilic condi-
tions, and the viable counts were determined. 
Statistical analysis
Results were expressed as mean±standard deviation 
using the SPSS software (version 17.0) (Chicago, Il-
linois, 2009) and Excel. One-way analysis of vari-
ance (ANOVA), followed by Turkey’s post-hoc test, 
was used for comparing the mean difference in in-
hibitory activities of extracts and antibiotics. The 
differences were considered significant at p<0.05. 
Ethical approval
The Eastern Cape Department of Health and the 
Govan Mbeki Research and Development Centre, 
University of Fort Hare, approved the study.
RESULTS
Extract yield
The total amount of crude extract obtained with 
the different solvents showed that methanol was 
quantitatively the best solvent for extraction, with a 
crude extract yield of 5.1 g (1.7%), followed by ace- 
tone 4.6 g (1.5%), ethanol 3.2 g (1.1%), water 3.1 g 
(1.0%), and ethyl acetate 1.3 (0.4%). Ethyl acetate, 
acetone and methanol extracts were dark brown 
in colour while ethanol and aqueous extracts ap-
peared as brown to light brown crystals. 
Antimicrobial susceptibility testing and deter-
mination of minimum inhibitory concentration
All the crude extracts tested in this study demon-
strated antimicrobial activity with zone diameters 
of inhibition ranging from 0 to 38 mm (Table 1). 
The highest zone diameter of 38 mm was recorded 
for the acetone extract, to which 87.5% of the clini-
cal strains were susceptible (Fig. 1). Zone diameters 
of inhibition for the acetone extract were signifi-
cantly different from the other extracts (p<0.05) as 
opposed to the control antibiotic (p>0.05) (Table 
1). Eleven (34.4%) and six (18.8%) of the 32 strains 
tested against the acetone and ethanol extracts 
respectively recorded susceptible zones of inhibi-
tion as opposed to the positive control which was 
resistant but the differences were not significant 
(p>0.05). 
The MIC values for the acetone extract ranged from 
1.25 to 5.0 mg/mL while those for amoxicillin and 
metronidazole ranged from 0.001 to 0.94 mg/mL 
and 0.004 to 5.0 mg/mL respectively (Table 2).  
Bactericidal activity
The acetone extract of C. molle exhibited consid-
erable bactericidal activity against the isolates at 
all concentrations tested over a 72-hour period. 
The test organisms were completely eliminated at 
a concentration of 2.5 and 5.0 mg/mL within 24 
hours (Fig. 2). No cells were killed in the first six 
hours of the experiment at all the extract concen-
trations tested.
DISCUSSION
Post-therapeutic antibiotic-resistant H. pylori re-
duces the cure rate of infection by up to 66% (12). 
With very few exceptions, the most commonly-
recommended treatment regimen (PPI, amoxicillin, 
and clarithromycin or metronidazole) now pro-
vides unacceptably low treatment successes (23), 
with approximately one in five patients requiring 
second and third-line therapies due to eradication 
failure (12). It should, therefore, not be surprising 
that all the clinical strains tested in this study were 
resistant to metronidazole and amoxicillin consid-
ering that they were isolated from patients who 
had been on treatment regimens involving these 
drugs (4). We were, therefore, probably dealing 
Table 1. Screening of crude extracts of C. molle against H. pylori isolates
Extract/
antibiotic
Mean zone 
diameter 
(mm)
 Inhibition zone 
diameter range 
(mm)
p value
 EA  A   E  M H2O CLR
EA 10.7±4.7    0-21 - 0.00 0.62 0.054 0.00 0.28
A 17.5±5.0   10-38 0.00 - 0.02 0.03 0.00 0.10
E 13.0±4.7   7-35 0.62 0.02 - 1.00 0.00 0.99
M 13.1±5.3   7-32 0.54 0.03 1.00 - 0.00 0.99
H2O  2.8±5.5   0-20 0.00 0.00 0.00 0.00 - 0.00
CLR 13.7±9.1   0-32 0.28 0.10 0.99 0.99 0.00 -
Data are mean±SD values of 33 independent determinations for each extract or control antibiotic. The   
mean difference was considered significant at p<0.05. A=Acetone; CLR=Clarithromycin; E=Ethanol; 
EA=Ethyl acetate; H2O=Aqueous; M=Methanol; SD=Standard deviation; -=No comparison  Njume C et al. Anti-Helicobacter pylori activity of Combretum molle
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Fig. 1. Anti-H. pylori activity of crude extracts of 
  C. molle by agar well diffusion method
with a small group of patients with a high level of 
post-therapeutic resistance confirmed by the high 
MIC values observed. 
Other  studies  have  reported  high  metronidazole 
and amoxicillin resistance in the developing world 
(1,4,5,24). Metronidazole resistance is an existing 
problem in this part of the world and is probably 
due to drug pressure because this inexpensive drug 
is also used in the treatment of gynaecological prob-
lems and protozoa infections (1,4) while amoxicil-
lin resistance can be attributed to the non-adher-
ence to drug-prescription protocols. Consequently, 
an increased eradication failure will be observed 
with treatment regimens involving these drugs. 
Antimicrobial susceptibility testing to establish 
resistance patterns, therefore, becomes imperative 
to guide empiric treatment. Other measures, such 
as strict antibiotic restriction practices, education 
of the population, and pharmacovigilance will go 
a long way to improve the management of antibi-
otic use in the developing world.
Our results showed that methanol was quantitative-
ly the best solvent for extraction. Different solvents 
may be employed in the extraction of antimicro-
bial compounds from plants; however, the success 
in the isolation process is largely dependent on the 
type of solvent used (25). The good extracting abili- 
ty of methanol recorded in this study corroborates 
findings of other studies (25-27), thus confirming 
this solvent as a good extractant of phytochemicals 
from Combretum species and other plants. How-
ever, the quantity of extract may not always relate 
proportionately to the activity as revealed by the 
low anti-H. pylori activity of the methanol extract 
recorded herein. Nevertheless, extracts with little 
or no activity in vitro may have properties similar 
to pro-drugs which are administered in an inac-
Table 2.   Minimum inhibitory concentration 
(90%) of C. molle and control antib- 
iotics (mg/mL)
H. pylori 
strain
MIC90 (mg/mL)
Acetone 
extract
Metroni- 
dazole
Amoxi- 
cillin
PE2A 1.25 2.50 0.02
PE5A 2.5 – –
PE9C 5 – 0.02
PE11A 1.25 – 0.94
PE11C 1.9 – 0.94
PE14C 1.25 – 0.02
PE26A 2.5 – 0.02
PE70A 2.5 – 0.02
PE76A 1.9 2.5 0.02
PE84C 1.9 – 0.02
PE93A 1.25 5 0.02
PE93C 2.5 – 0.02
PE102C 2.5 – 0.02
PE115A 2.5 5 0.02
PE155A – 1.9 0.02
PE162A 2.5 5 0.1
PE219A 1.25 1.9 0.02
PE252C 1.25 1.9 0.02
PE258C – 2.5 0.02
PE265C 2.5 – –
PE296C 1.25 5 0.02
PE308C 5 5 0.02
PE369A 2.5 – 0.02
PE369C 2.5 – 0.63
PE397C 1.25 5 0.02
PE402A 2.5 5 0.02
PE411A 1.9 – 0.63
PE411C 1.9 – 0.02
PE430A 2.5 – 0.02
PE430C 2.5 – 0.02
PE435A 2.5 – 0.94
PE466C 1.25 1.9 0.02
NCTC 
11638
2.5 0.004 0.001
Mean±SD 2.2±0.9 3.3±1.7 0.2±0.3
–=Value not within susceptible range. The re-
sults shown are representative of 33 independ-
ent experiments for each extract or control an-
tibiotic and duplicate determinations for each 
strain. MIC=Minimum inhibitory concentra-
tion; SD=Standard deviationAnti-Helicobacter pylori activity of Combretum molle Njume C et al.
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tive form. Their metabolites could be active in vivo 
(14).
The results of this study indicate that the ethanol 
and methanol extracts were only minimally active 
(Fig.  1). However, in a study on rats in Brazil by Nunes 
et al. (28), the ethanolic extract of the stem bark of 
a local Combretum species─C. leprosum─exhibited 
anti-ulcerogenic and gastro-protective effects by in-
creasing the volume and pH of gastric juice while 
decreasing the acid output (28). Although Nunes 
et al. did not investigate the antimicrobial activity 
of their extracts against H. pylori (28), the effects 
demonstrated by the crude ethanolic extract of C. 
leprosum in the animal model could be useful in 
preventing the development of severe pathological 
conditions in an H. pylori-infected mucosa.
The zone of inhibition diameters and percentage 
susceptibilities seem to decrease with increase in 
polarity of the solvent from ethanol to water (Fig. 
1), which may imply that the isolates were not very 
sensitive to the polar compounds of this plant or 
at least, not many anti-H. pylori compounds were 
extracted by polar solvents. However, the activity 
demonstrated by these extracts indicates their po-
tential as useful bioactive substances.
The acetone extract demonstrated remarkable acti- 
vity against the test strains in the entire study. This 
indicates that the active components of this plant 
are more soluble in acetone and have a good anti-
microbial potential. Further investigation may lead 
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to the isolation of potentially-useful compounds   
for the treatment of H. pylori infections. The activi- 
ty of this extract compared favourably with met-
ronidazole, with no significant differences between 
their mean MIC values (p>0.05). This is remarkable 
considering that all the clinical strains used in this 
study were resistant to the antibiotics.
The extract was also strongly bactericidal at a con-
centration of 2.5 and 5.0 mg/mL, with complete 
elimination of the organisms in 24 hours (Fig. 2). 
However, active components in the crude extract 
may be acting in synergism to produce greater an-
timicrobial effects (29). In any case, the acetone ex-
tract of C. molle may be considered a possible new 
source of compounds for the management of infec-
tions caused by resistant strains of H. pylori. This is 
particularly important in the study area given the 
current trend and ever-evolving nature of resistant 
H. pylori (4).  
Acetone is used for extracting mostly flavonoids 
and steroids (15,30,31). Flavonoids are known to 
be synthesized by plants in response to microbial 
infection (32,33), which may account for their an-
timicrobial activity against a wide range of organ-
isms. 
Several studies have reported on the good antimi-
crobial activity of the ethyl acetate fraction of Com-
bretum species (34,35) but H. pylori was not among 
the organisms tested. Our findings provide prelimi-
nary evidence that the ethyl acetate extract of C. Njume C et al. Anti-Helicobacter pylori activity of Combretum molle
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molle has very little activity against H. pylori. The 
aqueous extracts of C. molle also showed very little 
activity (6.3%) against H. pylori (Fig. 1). Other stud-
ies have also reported very low antimicrobial activi- 
ty of the aqueous extract of other members of the 
Combretaceae and other plants (15,35). Despite its 
availability and relatively low toxicity, water may 
still not be a suitable solvent for the extraction of 
anti-H. pylori compounds from C. molle.  
Conclusions
The results of the study provide preliminary sci-
entific validation of the traditional medicinal use 
of this plant in the treatment of infections symp-
tomatic of H. pylori. This plant may contain com-
pounds, mostly in the acetone crude extract that 
could be used as lead molecules for the synthesis 
of novel drugs against recurrent and resistant H. 
pylori infections. Isolation and characterization of 
the biologically-active constituents of the acetone 
extract of C. molle and a detailed assessment of their 
in-vivo potencies will add more value to their poten-
tial usefulness as anti-H. pylori agents. These aspects 
are already receiving attention in our group. 
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